• Kinney Michelle A O MAO Mayo Clinic, Rochester, MN, USA. Electronic address: kinney.michelle@mayo.edu., David M Nagorney, Daniel F Clark, Travis D O'Brien, Jonathan D Turner, Mary E Marienau, Darrell R Schroeder, and David P Martin.
• Mayo Clinic, Rochester, MN, USA. Electronic address: kinney.michelle@mayo.edu.
• J Clin Anesth. 2018 Dec 1; 51: 93-96.

Study ObjectivePartial hepatic resection reduces tumor burden in patients with metastatic neuroendocrine tumors, thereby improving quality and length of life. These procedures can be challenging as well as life-threatening. Our aim was to evaluate our patients' perioperative outcomes and propose a definition for an intraoperative carcinoid crisis relevant to this surgery, given its unique surgical considerations.DesignRetrospective study.SettingMayo Clinic, Rochester, Minnesota.PatientsOne hundred sixty-nine patients undergoing partial hepatic resection for metastatic neuroendocrine tumors between 1997 and 2015 were identified retrospectively from a surgical database at Mayo Clinic Rochester.InterventionsNone.MeasurementsIntraoperative carcinoid crisis for patients undergoing hepatic resection of neuroendocrine tumors was defined. Patients' medical records were reviewed and data were abstracted describing patient and procedural characteristics and perioperative outcomes.Main ResultsThere were no documented cases of carcinoid crisis (0.0%, 95% C.I. 0.0% to 2.2%). One patient developed clinical findings of an emerging carcinoid crisis, but was successfully treated with doses of octreotide and findings resolved in <10 min. Prophylactically 500 μg octreotide was given subcutaneously in 77% (130/169) of patients preoperatively.ConclusionsThere were no documented cases of carcinoid crisis (0.0%, 95% C.I. 0.0% to 2.2%). Adverse events were infrequent.Copyright © 2018 Elsevier Inc. All rights reserved.

37 keywords...

hide…